Articles related to SOLID TUMORS

The current real-world cohort study examines long-term survival outcomes in the 5 years after a COVID-19 hospitalization for adults with a solid malignancy. The study assessed the impact of vaccination status, vaccine platform, primary tumor site, and cancer treatment.

“Subcutaneous administration offers substantial workflow advantages. It can decrease chair time, reduce dependency on central lines, and allow for faster patient turnover.” – Dr. Aakash Desai

Afamitresgene autoleucel offers a novel approach to treating metastatic synovial sarcoma, with an overall response rate of 43.2% in clinical trials, providing a much-needed alternative to traditional chemotherapy.

Enhertu, now FDA approved for HER2-positive solid tumors, shows a notable objective response rate across pivotal trials, providing a significant new option for patients with advanced disease stages.

Recent advances in CAR T-cell therapy show significant promise in treating both blood cancers and solid tumors, offering durable responses and extended survival rates for patients previously facing limited options.

Understanding the nuances in diagnosing soft tissue masses is crucial for healthcare providers, as misdiagnosis can lead to delays in treatment and potentially worsen patient outcomes.